We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Citizen Petition Urges FDA to Invalidate Ranbaxy’s First-to-File Generic Exclusivity Status
Citizen Petition Urges FDA to Invalidate Ranbaxy’s First-to-File Generic Exclusivity Status
A new Citizen Petition contends the FDA should revoke Ranbaxy’s first-to-file market exclusivity status on several lucrative generic drugs due to a clear history of manufacturing problems and intentional false statements made by the Indian generics company.